Drug Topics

OCTOBER 28, 2023

The drug, marketed as Beyfortus, was approved by the FDA in July for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

FDA 98

FDA 98

STAT

OCTOBER 28, 2023

Recently, STAT launched a brand-new home for our subscribers to connect with each other and with their favorite STAT journalists. It’s called, appropriately, STAT+ Connect. There, you can find job postings; comment on STAT articles (since we have closed comments on article pages); discuss news events with other people who work in biotech, pharma, public health advocacy, PR, and more; read insights and extra material posted by STAT reporters and editors; and watch events, including live in

102

102

Pharma Marketing Network

OCTOBER 28, 2023

Patient-centricity is a concept that is gaining traction in the pharmaceutical industry. It is a shift from a traditional focus on drug development and marketing to a focus on the patient’s needs. This shift is being driven by advances in digital communication, which are allowing companies to better understand and meet the needs of their patients. In this article, we will explore the concept of patient-centricity, its impact on digital communication in pharma, the benefits it brings, and the cha

Communication 52

Communication 52

Roots Analysis

OCTOBER 28, 2023

On 26 October 2023, Eisai and Biogen’s Alzheimer’s drug, Leqembi, was found to be as effective as the current intravenous administration in removing toxic brain plaques. However, the review conducted by the drugmakers revealed that the rates of serious side effects were higher when using the drug in its subcutaneous injection form. The company’s analysis compared data from 72 early Alzheimer’s patients who received Leqembi through subcutaneous injection to prior pivotal t

40

40

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.